Get started
Sign in
Close

Research

Featured research

Truveta Research graphic announcing a Contraception journal study evaluating lidocaine and opioid use during IUD insertion.

Evaluating changes in lidocaine and opioid administration on the day of IUD insertion, 2018-2025

Authors: Nina B. Masters, PhD, MPH ⊕Truveta, Inc, Bellevue, WA, Karen G. Farrar, PhD ⊕Truveta, Inc, Bellevue, WA, Brianna M. Goodwin Cartwright, MS ⊕Truveta, Inc, Bellevue, WA, Patricia J. Rodriguez, PhD, MPH ⊕Truveta, Inc, Bellevue, WA, Duy Do, PhD ⊕Truveta, Inc,...
Read More
Respiratory virus monitoring report, data through December 2025

Real-time monitoring of respiratory virus-associated hospitalizations: Trends through December 2025 

Respiratory virus–associated hospitalizations increased substantially (+125.3%) in December 2025 and accounted for nearly 7% of all hospitalizations by the last week of the month. This increase was driven primarily by a rise in influenza-associated hospitalizations...
Read More
Thumbnail image for Truveta’s GLP-1 receptor agonist prescription trends report, featuring a stacked area chart background and text highlighting monitoring of prescription and dispense data from January 2019 to December 2025.

GLP-1 RA prescription trends: January 2019 – December 2025

As of December 2025, GLP-1 RA prescriptions account for more than 7% of all prescriptions. Tirzepatide continues to be the most prescribed anti-diabetic (ADM) and anti-obesity (AOM) medication (sold as Mounjaro and Zepbound, respectively) and showed the largest...
Read More
Truveta real-world evidence study examining delayed or absent first doses of measles, mumps, and rubella (MMR) vaccination, published in JAMA Network Open.

Delayed or absent first dose of measles, mumps, and rubella vaccination

New Truveta research in JAMA Network Open shows declining timely MMR vaccination since COVID-19, identifying early childhood vaccine delays as key predictors.

Read More
Graphic with the Truveta logo and the headline ‘Rising use of GLP-1 medications among women with PCOS,’ set on a blue background with stylized ascending bar shapes representing increasing medication use.

Rising use of GLP-1 medications among women with PCOS

Among women prescribed a semaglutide or tirzepatide medication, the percentage with a PCOS diagnosis increased from 4.6% in 2021 to 5.7% in 2025, a 23.9% relative increase. Nearly all PCOS patients prescribed semaglutide or tirzepatide also had obesity or type 2...
Read More
Text graphic with title and subhead Anemia among patients with chronic kidney disease and diabetes anemia burden and treatment research using EHR data

Exploring anemia burden and treatment patterns in patients with chronic kidney disease and diabetes

In patients with CKD and diabetes, anemia prevalence and severity increased from stage 1 to stage 5, with overall anemia rising from 46.4% to 85.0% and severe anemia from 2.5% to 11.8% Erythropoiesis-stimulating agents (ESAs) and IV iron use rose as hemoglobin levels...
Read More
evidence for safer ureteroscopy from Boston Scientific using Truveta Data

Boston Scientific finds reduced infection risk with pressure monitoring ureteroscope

Infections remain one of the most concerning complications following ureteroscopy (URS), a common procedure to examine or treat kidney stones. Even though URS is considered a safe and routine procedure, postoperative infections can lead to serious outcomes, including...
Read More

Featured research topics

GLP-1

Oncology

Flu/RSV

Measles

Cardiovascular